Research Center

About Us

The GCH Office of Child Health Research is the central coordination entity, which supports the overall vision of the hospital to conduct research that contributes to the global body of knowledge and advances public policy in response to the real needs of the pediatric population in the developing world.

GCH Primary Areas of Interest
➢ Hemato-oncology
➢ Genetics
➢ Endocrinology, Diabetes
➢ Infectious Diseases
➢ Nephrology
➢ Neurological Disorders
➢ Developmental Disorders
➢ Cardiology
➢ Audiology

Research Therapeutic Areas Team Leads

Therapeutic LeadTherapeutic Area
Prof. Jessie Githang’aHemato-oncology
Dr. Doreen KarimiHemato-oncology
Dr. Sam GwerNeurological Disorders
Dr. Joseph MbuthiaInfectious Diseases
Dr. Doris KinuthiaNephrology
Dr. Catherine MutindaGenetics
Dr. Renson MukhwanaEndocrinology, Diabetes
Dr. Florence OringeDevelopmental Disorders
Dr. Sean Del RosseCardiology
Dr. Mark Awori Cardiology

Clinical Trials Experience

2012:TADO – A phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and
Placebo in Pediatric Patients with Sickle Cell Disease
2015/2016: HESTIA 1 – Multicenter, Open-label, Randomized, Pharmacokinetic (PK) and Pharmacodynamic
(PD) Dose-ranging, Phase 2 Study of Ticagrelor followed by a Double-blind, randomized,
Parallel group, Placebo-controlled 4 weeks extension Phase in Pediatric Patients with
Sickle Cell Disease
2017:GBT 031 – A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study of GBT
440 Administered Orally to Patients with Sickle Cell Disease
2018:GBT 034 – An Open-label Extension Study of Voxelotor (GBT 440) Administered Orally to
Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials
2018:HESTIA 4 – A Multi-centre, Phase 1, Open-label, Single-Dose Study to Investigate
Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to less than 24 months,
with Sickle Cell Disease
2019:HESTIA 3 – A Randomised, Double-Blind, Parallel-Group, Multi-centre, Phase 3 Study to
Evaluate the Effect of Ticagrelor vs Placebo in Reducing the Rate of Vaso-Occlusive Crises
in Pediatric Patients with Sickle Cell Disease
2020:IMARA – A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with
Sickle Cell Disease

i. Research4Life
ii. TCC Africa
■ Open Access Research Discoveries Solutions
✓ R Discovery
✓ SciELO
✓ Open Research Library
✓ Dimensions
✓ Meta
✓ Scienceopen
■ Open Access Repositories
✓ African Digital Research Repositories
✓ AfricArXiv
■ Journal Selection Strategy:
✓ African Journals Online
✓ Directory of Open Access Journals
✓ Dimensions